Failure to remit at endpoint · patients with depression
Paroxetine probably leads to higher failure to remit at endpoint compared with mirtazapine (moderate certainty).
1 finding from 1 review
SMD at endpoint · patients with depression
1 finding from 1 review
Failure to respond at 1‐4 weeks · patients with depression
1 finding from 1 review
Failure to complete ‐ any cause ‐ · patients with depression
Paroxetine showed no clear difference in failure to complete ‐ any cause ‐ compared with mirtazapine (moderate certainty).
1 finding from 1 review
Participants with at least some Side Effects · patients with depression
Paroxetine showed no clear difference in participants with at least some Side Effects compared with mirtazapine (moderate certainty).
1 finding from 1 review
Failure to respond at endpoint (6‐12 weeks) · patients with depression
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with nefazodone (moderate certainty).
1 finding from 1 review
Failure to respond at 1‐4 weeks · patients with depression
1 finding from 1 review
Failure to respond at 16‐24 weeks · patients with depression
Paroxetine showed no clear difference in failure to respond at 16‐24 weeks compared with nefazodone (moderate certainty).
1 finding from 1 review
Failure to remit at endpoint · patients with depression
1 finding from 1 review
SMD at endpoint · patients with depression
1 finding from 1 review
Failure to complete ‐ any cause ‐ · patients with depression
Paroxetine showed no clear difference in failure to complete ‐ any cause ‐ compared with nefazodone (moderate certainty).
1 finding from 1 review
Participants with at least some Side Effects · patients with depression
Paroxetine showed no clear difference in participants with at least some Side Effects compared with nefazodone (moderate certainty).
1 finding from 1 review
Failure to respond at endpoint (6‐12 weeks) · patients with depression
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with reboxetine (moderate certainty).
1 finding from 1 review
> 50% reduction in depressive symptoms · people with epilepsy and depression
Paroxetine showed no clear difference in > 50% reduction in depressive symptoms compared with doxepin (moderate certainty).
1 finding from 1 review
Depressive symptoms · people with epilepsy and depression
1 finding from 1 review
Seizure frequency · people with epilepsy and depression
1 finding from 1 review
Treatment withdrawal · people with epilepsy and depression
Paroxetine showed no clear difference in withdrawals compared with doxepin (moderate certainty).
1 finding from 1 review
Cognitive function · people with epilepsy and depression
1 finding from 1 review
Quality of life · people with epilepsy and depression
1 finding from 1 review
Adverse effects · people with epilepsy and depression
1 finding from 1 review